

Distinguished Lecture Series

Tuesday, November 12, 12:00pm

Brady Auditorium | [Zoom Access](#)

Join us in person for lunch

INDUCED PROXIMITY: EXPLORING NEW THERAPEUTIC MODALITIES

Craig Crews, PhD

John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, of Pharmacology, and of Management

Needs:

Clinical oncology needs additional, novel therapeutic modalities. This lecture introduces the concept of 'induced proximity' as the bases for three novel therapeutic modalities

Objectives:

1. Induced Proximity as a the basis for novel therapeutic modalities.
2. The differences/similarities between molecular glues and heterobifunctional molecules.
3. The concept of "Hold and Kill" mechanism to treat cancer.



Dr. Craig Crews is the John C. Malone Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the University of Virginia with a BA in Chemistry and received his PhD from Harvard University in Biochemistry.

Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory has pioneered the use of small molecules to control intracellular protein levels. In 2003, he co-founded Proteolix, Inc., whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix's purchase by Onyx Pharmaceuticals in 2009, Dr. Crews has focused on a new drug development technology, which served as the founding intellectual property for his latest New Haven-based biotech venture, Arvinas, Inc.

Currently, Dr. Crews serves on several editorial boards and was Editor of Cell Chemical Biology (2008-2018). In addition, he has received numerous awards and honors

